How Are Responsibilities Divided for Authorized Representatives in Overseas Registration of Sterilization and Disinfection Equipment?

Answer

An authorized representative for sterilization and disinfection equipment in overseas registration is not merely a contact person but a statutory role with legal liaison and compliance obligations. Manufacturers must first determine whether the target country regulates the product as a medical device, then select the appropriate registration pathway based on risk classification—such as FDA 510(k), EU MDR Notified Body assessment, or local approval in GHWP member states. The manufacturer remains responsible for the authenticity of technical documentation, product safety, and timely reporting obligations.

Applicable Scenarios and Core Issues

When exporting sterilization and disinfection equipment to overseas markets, manufacturers are typically required to appoint an authorized representative or local agent in the target country. Many companies incorrectly view this role as a simple "mailbox," but the regulatory responsibilities go far beyond that. This article analyzes the boundaries of the authorized representative's role, the control manufacturers must retain, and how to avoid registration failures or post-market risks due to unclear responsibility division.

Applicable scenarios include: first-time registration in the target country, expanding overseas after holding an NMPA registration certificate, changing the original authorized representative, multi-country joint registration, and managing liability transitions during adverse events or regulatory inspections. The core question is not whether to appoint an authorized representative, but how to clearly define the respective duties of the authorized representative and the manufacturer.

Sterilization and disinfection equipment is generally classified as medium- to high-risk medical devices in many countries. The U.S. FDA manages these products based on classification and exemptions, the EU MDR requires a European Authorized Representative, and GHWP member states such as Saudi Arabia, Thailand, the Philippines, Malaysia, and Brazil have their own local agent requirements. The division of responsibilities directly affects the submission of technical files, declarations of conformity, certificate holding, and post-market vigilance obligations.

Manufacturers need to clarify: To whom is the registration certificate issued by the regulatory authority? Does the authorized representative control the certificate? What happens to the certificate if the authorized representative is changed? If these issues are not fixed in written agreements at the project's outset, significant compliance risks can arise later.

Registration Decision Logic

Step 1: Determine whether sterilization and disinfection equipment is regulated as a medical device in the target country. Some countries classify large steam sterilizers as medical devices, others may categorize them as active medical devices, and some have separate classification criteria for sterilizer accessories. It is advisable to consult the target country's regulatory classification list or use a pre-submission process to confirm.

Step 2: Assess the risk class and registration pathway. For example, U.S. FDA sterilization and disinfection equipment is typically Class II and requires a 510(k) submission; under EU MDR, such products are usually Class IIa or IIb and require Notified Body involvement; most Southeast Asian countries follow the ASEAN Medical Device Directive or their own classification, and high-risk products may require local evaluation or acceptance of other market approvals as reference.

Step 3: Evaluate whether existing technical files can be reused. Existing NMPA registration dossiers, CE technical files, FDA 510(k) documents, ISO 13485 certificates, and MDSAP certificates can serve as a foundation. However, requirements for biocompatibility, performance validation, sterilization shelf life, label language, and clinical evaluation vary by country and cannot be simply copied.

Step 4: Confirm the appointment method for the local agent and authorized representative. Some countries require the local agent to be designated before submitting the registration application, and the agent must have a registered office address and contact person locally. The manufacturer must sign a formal agreement with the agent clearly defining responsibilities for after-sales service, adverse event reporting, regulatory communication, and certificate custody.

Step 5: Establish a post-market maintenance mechanism. Periodic testing, software updates, labeling changes, and serious incident notifications for sterilization and disinfection equipment rely on the authorized representative's cooperation. Manufacturers should establish a clear information flow process with the authorized representative and maintain records.

Documents and Evidence

When preparing documentation, manufacturers should focus on four categories of evidence: product technical files, quality management system evidence, clinical/performance safety evidence, and labels/instructions for use. Technical files should include device description, operating principle, materials list, sterilization parameters, performance tests, and software version information. Quality system evidence includes ISO 13485 certificates, internal audit reports, management review records, and adverse event monitoring procedures.

Performance safety evidence depends on product type. For example, steam sterilizers require validation data on heat distribution, penetration, residual water, and biological indicator challenges; ethylene oxide sterilizers require data on residual levels within acceptable limits, ventilation capacity, and environmental monitoring; low-temperature plasma sterilizers require data on material compatibility, sterilization effectiveness, and possible chemical by-products. Whether this evidence is accepted by the target country usually needs to be confirmed in advance by the authorized representative or local agent.

Labels and instructions must be localized. Many sterilization and disinfection devices are exported to non-English-speaking countries, where local regulators require warnings, parameters, and emergency procedures in the local language. The authorized representative is responsible for assisting in confirming label compliance, but the accuracy and scientific validity of label content remain the manufacturer's responsibility.

For multi-country registration within GHWP member states, manufacturers can structure technical files in a modular format, using a set of master files plus country-specific differences to reduce redundant preparation costs. The authorized representative can assist in verifying specific national requirements but cannot replace the manufacturer in providing raw data.

Common Mistakes

• Treating the authorized representative as the registration lead. Authorized representatives usually do not write technical files or sign on behalf of the manufacturer. If the company outsources all registration work without reviewing the content submitted by the agent, risks are high.
• No clear agreement on intellectual property and data rights. Without explicit confidentiality and data ownership clauses, technical files, test data, and source code may be withheld or delayed during a change of agent.
• Ignoring the certificate holder. In some countries, only the authorized representative can hold the registration certificate; in others, the manufacturer can apply and designate the representative as contact. Unawareness of this can lead to loss of control over the certificate.
• Unclear adverse event reporting path. If a sterilization failure, burn, or chemical leak occurs, the manufacturer must report to the regulator within specific timeframes. If the authorized representative lacks a fixed internal escalation channel, delays can occur.
• No pre-assessment of post-market changes. Software upgrades, sterilization parameter changes, or changes in key suppliers may require re-registration or notification. Some companies change without consulting the authorized representative, leading to certificate invalidation.
• Neglecting renewal and fee obligations. Certificates have expiry dates and require periodic renewal. The authorized representative may not remind the company due to fee or contract issues, and the company lacks an internal renewal calendar, eventually causing the certificate to lapse.

Enterprise Preparation Checklist

• Initial regulatory classification assessment table for target countries: local classification, risk class, exemption status, and registration pathway.
• Existing registration documentation inventory: NMPA registration certificates, CE certificates, FDA clearance letters, ISO 13485 certificates, MDSAP certificates, etc.
• Authorized representative due diligence form: agent qualifications, local office address, regulatory agent experience, and vigilance handling capability.
• Authorized representative agreement template: covering confidentiality, intellectual property, data access, certificate custody, notification obligations, breach liability, and termination conditions.
• Modular technical file directory: master files, country-specific differences, and annex list.
• Performance validation document list: sterilization effectiveness validation, safety testing, electromagnetic compatibility, and material compatibility.
• Label and instruction checklist: local language, text warnings, unit conversions, and graphical symbols.
• Post-market surveillance procedures: adverse event reporting process, internal timelines, authorized representative contact, and annual compilation.
• Renewal calendar and fee budget: expiry date for each registration, review cycle, and agent service fees.

AIMEILI Regulatory Interpretation and Business Impact

The most common misconception is viewing the authorized representative as an "outsourced" party. In reality, the authorized representative is a statutory role in the regulatory chain; the manufacturer bears ultimate responsibility for product safety, while the authorized representative handles local liaison and compliance submissions. This is not a simple buyer-seller service relationship.

At the project's early stage, manufacturers should first conduct target-country regulatory research before negotiating the agent agreement. It is recommended to first create a gap table between existing technical documents and target-country requirements to confirm which tests need to be supplemented. This way, when selecting an authorized representative, the focus is not only on price but also on their registration experience and technical understanding.

Regarding document reuse, quality system evidence, basic performance validation reports, and product design files have high reuse potential; biocompatibility data may require additional local-specific testing; and critical sterilization parameters—such as exposure time, temperature, humidity, and concentration—should be aligned with local standards. Language conversion is not just translation; it involves localization of measurement units, symbols, and warning statements.

The authorized representative, certificate control, changes, and renewals are the most undervalued aspects in overseas registration projects. The certificate should ideally be registered in the manufacturer's name. If local regulations mandate that it must be in the agent's name, the agreement must stipulate that the agent cannot unilaterally transfer or cancel the certificate, and should define custody methods and transfer conditions.

For multi-country registration, companies should base their work on one set of technical files and have authorized representatives provide local difference lists separately. The company centrally maintains the master file version to avoid confusion across countries. A unified change management process should be established to assess whether changes affecting safety or performance require notification or re-registration in each country before execution by the corresponding authorized representative.

Common Follow-up Questions

Can an authorized representative serve multiple competing companies?

Yes, provided this does not conflict with confidentiality clauses in the agent agreement. However, when an authorized representative serves multiple manufacturers, there is a risk of information mixing or response delays. It is advisable to stipulate a dedicated contact person, response time, and service level in the agreement.

If we change the authorized representative, can the existing registration certificate still be used?

This depends on local regulations. Some countries require the certificate to be bound to the manufacturer, and a change of authorized representative requires a change application within a specified period. Other countries tie the certificate to the authorized representative, and a change may require identifying a new entity and completing a transfer or cancellation, followed by a new application. Companies should consult the local agent and regulatory authority before making the change and retain complete transfer records.

Do sterilization and disinfection devices always require clinical evaluation?

Most sterilization and disinfection devices can demonstrate compliance through performance validation, biological indicator challenges, and safety testing; clinical trials are not necessarily required. However, some novel sterilization methods or devices used for sterilizing implantable instruments may require clinical evidence. The need should be determined based on the target country's classification and intended use. Early confirmation with the local agent can reduce rework.

What are the time requirements for adverse event reporting by authorized representatives?

Time limits vary by regulatory body. For example, the U.S. FDA may require reports of serious adverse events within 30 days, the EU MDR has deadlines for serious incidents, and GHWP member states also have their own reporting periods. Authorized representatives should be familiar with local reporting pathways, but manufacturers must establish an internal event assessment process to ensure information is conveyed to the authorized representative promptly and reports are initiated.

Content Review and Applicability

This content is authored by the AIMEILI Regulatory Editorial Team and professionally reviewed by the AIMEILI Medical Device International Registration Project Group. Information is prioritized from official regulatory agencies, international organizations, standards bodies, and publicly available regulatory materials; industry media and project experience are used only as secondary references. This article is intended for preliminary understanding, document preparation, and project planning. It does not replace formal requirements from target-country regulatory authorities, testing conclusions, or legal opinions.